Krystal Biotech (KRYS) Net Cash Flow Growth (3y) (2019 - 2026)
Powered by 
Analysis
Krystal Biotech (KRYS) Net Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -35.85% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 106.37% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 67.39% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.55% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 52.78% |
| 10 | Krystal Biotech | 10.61 Bn | 9.76 Bn | 112.79 Mn | -36.28% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -36.28% |
| Mar 31, 2026 | 32.00% |
| Dec 31, 2025 | 84.34% |
| Sep 30, 2025 | 47.51% |
| Jun 30, 2025 | 42.11% |
| Mar 31, 2025 | 20.41% |
| Dec 31, 2024 | -36.11% |
| Sep 30, 2024 | 38.38% |
| Jun 30, 2024 | 43.82% |
| Mar 31, 2024 | -84.58% |
| Dec 31, 2023 | -1.57% |
| Sep 30, 2023 | 131.82% |
| Jun 30, 2023 | 6.63% |
| Mar 31, 2023 | -42.56% |
| Dec 31, 2022 | -49.71% |
| Sep 30, 2022 | -81.02% |
| Jun 30, 2022 | -37.00% |
| Mar 31, 2022 | -133.42% |
| Dec 31, 2021 | -1.41% |
| Sep 30, 2021 | -121.32% |